IPC signs MoUs with PMBI & NIPER Hajipur to Boost Drug Quality and Pharmacovigilance

<h2>MoUs to Strengthen Drug Quality, Research and Patient Safety</h2> <p>Under the leadership of <strong>Prime Minister Shri Narendra Modi</strong>, the <span class="key-term" data-definition="Indian Pharmacopoeia Commission — statutory body under the Ministry of Health that sets standards for medicines and ensures their quality (GS3: Health/Pharma)">IPC</span> signed two Memoranda of Understanding on 24 April 2026 – one with the <span class="key-term" data-definition="Pharmaceuticals &amp; Medical Devices Bureau of India – agency under the Ministry of Chemicals and Fertilizers that regulates pharmaceuticals and medical devices (GS3: Health/Industry)">PMBI</span> and another with the <span class="key-term" data-definition="National Institute of Pharmaceutical Education and Research, Hajipur – Institute of National Importance offering advanced pharmaceutical education and research (GS3: Education/Science)">NIPER Hajipur</span>. The agreements aim to improve drug quality, expand pharmacovigilance and promote rational use of medicines across the country.</p> <h3>Key Developments</h3> <ul> <li>PMBI will forward randomly selected batches of medicines sold at <span class="key-term" data-definition="Pradhan Mantri Bhartiya Janaushadhi Kendras – government‑run outlets that dispense affordable generic medicines (GS3: Health/Access)">PMBJKs</span> to IPC for stringent quality testing.</li> <li>Both agencies will promote the <span class="key-term" data-definition="National Formulary of India – official compendium of approved medicines and dosage forms used for rational prescribing (GS3: Health)">NFI</span> in all Jan Aushadhi stores to ensure rational drug use.</li> <li>IPC and PMBI will display the <span class="key-term" data-definition="Pharmacovigilance Programme of India – national system for monitoring adverse drug reactions (GS3: Health)">PvPI</span> QR code and the toll‑free helpline (1800‑180‑3024) at every PMBJK, encouraging reporting of <span class="key-term" data-definition="Adverse drug reaction – any harmful or unintended response to a drug (GS3: Health)">ADR</span> and strengthening patient safety.</li> <li>Joint sensitisation, awareness and training programmes will be organised for pharmacists on rational drug use, ADR reporting and the role of pharmacists in safeguarding public health.</li> <li>IPC‑NIPER collaboration will focus on research on impurity profiling, especially <span class="key-term" data-definition="Genotoxic impurities (nitrosamines) – chemical contaminants that can damage DNA and are a global safety concern (GS3: Health/Regulation)">genotoxic impurities</span>, and on developing analytical methods and reference standards for biologics, biosimilars and emerging cell‑ and gene‑therapy products.</li> <li>Faculty exchange, shared use of advanced analytical instrumentation, internships, fellowships and joint publications will be facilitated between the two institutions.</li> </ul> <h3>Important Facts</h3> <p>The MoUs were signed by the <strong>Indian Pharmacopoeia Commission</strong> and the <strong>Pharmaceuticals &amp; Medical Devices Bureau of India</strong>, both under the Ministry of Health and the Ministry of Chemicals and Fertilizers respectively. <strong>NIPER Hajipur</strong> is an autonomous institute under the Department of Pharmaceuticals. The agreements cover quality testing, pharmacopoeial standard setting, capacity building, and creation of reference standards for emerging therapies.</p> <h3>UPSC Relevance</h3> <p>These initiatives illustrate the government's multi‑pronged approach to health governance – a frequent topic in GS III (Health, Social Justice and Welfare). Understanding the roles of bodies like <span class="key-term" data-definition="Indian Pharmacopoeia Commission — statutory body under the Ministry of Health that sets standards for medicines and ensures their quality (GS3: Health/Pharma)">IPC</span>, <span class="key-term" data-definition="Pharmaceuticals &amp; Medical Devices Bureau of India – agency under the Ministry of Chemicals and Fertilizers that regulates pharmaceuticals and medical devices (GS3: Health/Industry)">PMBI</span> and <span class="key-term" data-definition="National Institute of Pharmaceutical Education and Research, Hajipur – Institute of National Importance offering advanced pharmaceutical education and research (GS3: Education/Science)">NIPER</span> helps candidates answer questions on drug regulation, public‑health infrastructure and the promotion of affordable medicines.</p> <h3>Way Forward</h3> <p>Effective implementation will require systematic sampling of Jan Aushadhi medicines, robust laboratory capacity at IPC, and widespread awareness among pharmacists about <span class="key-term" data-definition="Pharmacovigilance Programme of India – national system for monitoring adverse drug reactions (GS3: Health)">PvPI</span>. Strengthening research on <span class="key-term" data-definition="Genotoxic impurities (nitrosamines) – chemical contaminants that can damage DNA and are a global safety concern (GS3: Health/Regulation)">genotoxic impurities</span> will align India with global safety norms. Continuous monitoring, periodic audits and scaling up of training programmes will ensure that the objectives of the MoUs translate into tangible improvements in drug quality and patient safety across the nation.</p>